Affinity finds potent SARS-CoV-2 antibodies Australian cancer therapeutics company Affinity Biosciences has discovered potent SARS-CoV-2 antibodies with potential therapeutic applications against the novel coronavirus.
Hansa licenses enzyme pretreatment for gene therapy Hansa Biopharma has entered into an agreement with Sarepta Therapeutics for an exclusive worldwide license to develop and promote imlifidase as a pretreatment for gene therapy treatment of Duchenne muscular dystrophy and limb-girdle muscular dystrophy.
Inimmune gets grant for vaccine technology Montana-based Inimmune received a $2 million grant from the U.S. National Institute for Allergy and Infectious Diseases to develop novel adjuvant and delivery systems for vaccines.
J&J's Ebola vaccine approved by EU Johnson & Johnson announced that the European Commission granted marketing authorization for its Janssen Pharmaceutical Ebola vaccine regimen for the prevention of Ebola virus disease.
GoldenBiotech moves COVID-19 drug to phase II Golden Biotechnology (GoldenBiotech), a Taiwanese-based biopharmaceutical company, has received U.S. Food and Drug Administration approval to begin a phase II clinical trial of antroquinonol on COVID-19 patients in the U.S.